卡瑞利珠单抗治疗晚期转移性食管癌的临床疗效及安全性分析  

Clinical Efficacy and Safety Analysis of Camrelizumab in the Treatment of Advanced Metastatic Esophageal Cancer

作　　者：俞强 YU Qiang(Department of Oncology,Nanyang Yuxi Jianhe Hospital,Nanyang Henan 474500,China)

机构地区：[1]南阳豫西健和医院肿瘤内科,河南南阳474500

出　　处：《临床研究》2025年第1期65-68,共4页Clinical Research

摘　　要：目的探究转移性食管癌的晚期治疗中应用卡瑞利珠单抗的价值。方法选取南阳豫西健和医院2021年8月至2024年1月期间收入的64例转移性食管癌晚期患者,依据治疗方案的差异,将样本划分为对照组(n=32)采用常规化疗(紫杉醇+奈达铂)、而研究组(n=32)在对照组治疗方法的基础上额外使用卡瑞利珠单抗治疗,3周为1个治疗周期,以上两组均治疗4个周期。分析两组临床疗效、免疫功能指标、免疫检查点情况、肿瘤标志物、日常生存质量及不良反应情况方面的差异。结果研究组疾病控制率高于对照组,差异具有统计学意义(P<0.05)。治疗后,两组CD4^(+)T水平与治疗前比较,差异无统计学意义(P>0.05),CD8^(+)T水平均低于治疗前,CD3^(+)T、CD4^(+)T/CD8^(+)T均高于治疗前,且研究组变化程度均高于对照组,差异均有统计学意义(P<0.05)。治疗后,两组程序性细胞死亡受体1(PD-1)以及程序性死亡配体1(PD-L1)均低于治疗前,且研究组低于对照组,差异均有统计学意义(P<0.05)。治疗后,两组肿瘤标志物水平均低于治疗前,且研究组低于对照组,差异均有统计学意义(P<0.05)。治疗后,两组QLQ-OES18量表评分均高于治疗前,且研究组高于对照组,差异均有统计学意义(P<0.05)。治疗后,两组不良反应发生情况比较,差异无统计学意义(P>0.05)结论在常规化疗基础上联合应用卡瑞利珠单抗治疗转移性食管癌,能够改善患者免疫指标、免疫检查点、肿瘤标志物水平,显著提升疾病控制率,提高日常生存质量,保障用药安全性,具有临床应用意义。Objective To explore the value of Camrelizumab in the treatment of advanced metastatic esophageal cancer.Methods A total of 64 patients with advanced metastatic esophageal cancer admitted to Nanyang Yuxi Jianhe Hospital from August 2021 to January 2024 were selected.Based on differences in treatment protocols,the sample was divided into a control group(n=32)receiving conventional chemotherapy(paclitaxel+nedaplatin)and a study group(n=32)receiving additional Camrelizumab treatment alongside the control method.Each treatment cycle lasted 3 weeks,with both groups undergoing 4 cycles of treatment.Differences in clinical efficacy,immune function indicators,immune checkpoint levels,tumor markers,quality of life,and adverse reactions were analyzed between the two groups.Results The disease control rate in the study group was higher than that in the control group,with a statistically significant difference(P<0.05).After treatment,there were no significant differences in CD4^(+)T cell levels between the two groups compared to before treatment(P>0.05).The levels of CD8^(+)T cells decreased compared to before treatment,while CD3^(+)T cells and the ratio of CD4^(+)T/CD8^(+)T increased,with the study group showing greater changes than the control group,all of which were statistically significant(P<0.05).After treatment,levels of programmed cell death receptor 1(PD-1)and programmed death ligand 1(PD-L1)in both groups were lower than before treatment,with the study group showing lower levels than the control group,with statistically significant differences(P<0.05).Tumor marker levels decreased in both groups after treatment,and the study group had significantly lower levels than the control group(P<0.05).The scores on the QLQ-OES18 quality of life questionnaire for both groups increased after treatment,with the study group scoring higher than the control group,showing a statistically significant difference(P<0.05).There were no statistically significant differences in the incidence of adverse reactions between the two groups(P>

关 键 词：卡瑞利珠 单抗治疗 晚期 转移性食管癌 临床疗效 

分 类 号：R735.1[医药卫生—肿瘤]